Mikrogen

The companies are co-developing an assay that differentiates previously infected, seropositive Lyme disease patients from newly infected individuals.

The company has signed an agreement with biopharmaceutical firm SuppreMol to use its UNIarray technology to identify autoantibody signatures of SLE patients enrolled in a phase IIa study of SuppreMol's lead therapeutic SM101.

In separate deals announced this past week, the German biotech firm will distribute assays developed by Asuragen, and co-develop, co-manufacture, and co-market assays with Mikrogen.

The company is collaborating with fellow German biotech firm Mikrogen to identify autoantibody signatures typical of various infectious diseases.

The German firms said this week that they have conducted a feasibility study for identifying autoantibody signatures in infectious diseases that may be useful for future diagnostics.

The firms are working on infectious disease diagnostics using Protagen's UNIarray platform.

The UK's Human Fertility and Embryology Authority calls for consumer genetic testing companies to warn customers that testing could uncover family secrets, according to the Guardian.

The New York Times reports that United Nations delegates have been discussing how to govern the genetic resources of the deep sea.

Researchers have transplanted edited cells into mice that appear to combat cocaine addiction, New Scientist reports.

In PNAS this week: analysis of proteolytic enzymes secreted by circulating tumor cells, phylogenetic study of Fv1 evolution, and more.